ESA Use In Chronic Kidney Disease Will Get Second MedCAC Review

Medicare coverage of Amgen's Aranesp and other erythropoiesis-stimulating agents in chronic kidney disease is the topic for a meeting by the Medicare Evidence Development and Coverage Advisory Committee on Jan. 19.